Literature DB >> 17240560

A global pandemic influenza vaccine action plan.

Marie Paule Kieny1, Alejandro Costa, Joachim Hombach, Peter Carrasco, Yuri Pervikov, David Salisbury, Michel Greco, Ian Gust, Marc LaForce, Carlos Franco-Paredes, José Ignacio Santos, Eric D'Hondt, Guus Rimmelzwaan, Ruth Karron, Keiji Fukuda.   

Abstract

In case of an influenza pandemic, the world will be in a situation where potential vaccine supply will fall short by several billion doses from global needs. The World Health Organization (WHO) convened in Geneva on May 2-3, 2006 a consultation of all stakeholders in influenza vaccines and immunization to identify practical solutions to fill this gap. The consultation resulted in a global action plan outlining promising specific strategies to increase influenza vaccine production and surge-capacity before and during an influenza pandemic. Although the timing and severity of the next influenza pandemic cannot be predicted, vaccines are considered the one of the most important medical interventions for reducing morbidity and mortality if and when such an event occurs. Despite this acknowledged role, current limitations on influenza vaccine manufacturing capacity mean that, should a pandemic virus emerge in the near future, vaccine supplies would fall short of the anticipated global demand by several billion doses. Concern about this situation was formally acknowledged in May 2005, when the World Health Assembly approved a resolution [1] on strengthening pandemic influenza preparedness and response. That resolution called on the World Health Organization (WHO) to seek solutions with international and national partners, including the private sector, to reduce the present global shortage of influenza vaccines. More specifically, the resolution asked WHO to look at strategies for economizing on the use of antigen and transferring production technologies from industrialized to developing countries. In response to this request, WHO convened a consultation from 2-3 May 2006 attended by representatives of the major stakeholders in the area of influenza vaccines and immunization. The consultation had two main objectives: (1) To prepare a global action plan with specific short-, medium-, and long-term activities designed to increase influenza vaccine production and surge-capacity, to identify key obstacles and driving forces, and to estimate funding needs.(2) To strengthen the engagement and collaboration of key partners and stakeholders.

Mesh:

Substances:

Year:  2006        PMID: 17240560     DOI: 10.1016/j.vaccine.2006.07.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  Strategies for improving influenza immunization rates among hard-to-reach populations.

Authors:  David Vlahov; Micaela H Coady; Danielle C Ompad; Sandro Galea
Journal:  J Urban Health       Date:  2007-07       Impact factor: 3.671

2.  Intradermal delivery of vaccines: potential benefits and current challenges.

Authors:  J K Hickling; K R Jones; M Friede; D Zehrung; D Chen; D Kristensen
Journal:  Bull World Health Organ       Date:  2011-01-05       Impact factor: 9.408

3.  Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.

Authors:  Renée A J van Boxtel; Pauline Verdijk; Otto J de Boer; Elly van Riet; Tjeert T Mensinga; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets.

Authors:  Jørgen de Jonge; Harry van Dijken; Femke de Heij; Sanne Spijkers; Justin Mouthaan; Rineke de Jong; Paul Roholl; Eduardo Alfredo Adami; Milena Apetito Akamatsu; Paulo Lee Ho; Livia Brunner; Nicolas Collin; Martin Friede; José A Ferreira; Willem Luytjes
Journal:  NPJ Vaccines       Date:  2020-05-11       Impact factor: 7.344

Review 5.  [What is verified for travel vaccinations?]

Authors:  Tomas Jelinek
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

6.  Seasonal trivalent inactivated influenza vaccine protects against 1918 Spanish influenza virus infection in ferrets.

Authors:  Melissa B Pearce; Jessica A Belser; Kortney M Gustin; Claudia Pappas; Katherine V Houser; Xiangjie Sun; Taronna R Maines; Mary J Pantin-Jackwood; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

7.  The first influenza pandemic in the new millennium: lessons learned hitherto for current control efforts and overall pandemic preparedness.

Authors:  Carlos Franco-Paredes; Peter Carrasco; Jose Ignacio Santos Preciado
Journal:  J Immune Based Ther Vaccines       Date:  2009-08-07

8.  Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines.

Authors:  Steven F Baker; Aitor Nogales; Luis Martínez-Sobrido
Journal:  Future Virol       Date:  2015-06       Impact factor: 1.831

9.  A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings.

Authors:  Rebecca Pellett Madan; Maria Tan; Ana Fernandez-Sesma; Thomas M Moran; Sukru Emre; Andrew Campbell; Betsy C Herold
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

10.  Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines.

Authors:  George Milne; Joel Kelso; Heath Kelly
Journal:  J R Soc Interface       Date:  2009-09-15       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.